Our study indicates that CD63+ CAFs in the TME constitute a survival niche for BCs that can protect them from tamoxifen during cancer progression, which suggests that CD63+ CAFs may serve as a novel therapeutic target to enhance tamoxifen sensitivity in breast cancer. The gene discussed is CD63; the disease is breast carcinoma.